How did NeuroPace's revenue and expenses trend in Q4 2024?

NeuroPace's revenue and expenses trends in Q4 2024 are not currently available. However, we can infer some potential trends based on the available data.

1. **Revenue Trend**: NeuroPace has a history of surpassing consensus revenue estimates, as evidenced by its performance in Q3 2024, where it reported a 28% increase in revenue compared to the previous year, reaching $21.1 million. This suggests a strong revenue growth trajectory, which likely continued in Q4 2024.
2. **Expense Trends**: NeuroPace's gross margin was reported at 73.2% for Q3 2024, indicating efficient cost management. The company's R&D expenses increased to $5.8 million in Q3 2024, up from $4.8 million in the same period of 2023, driven by personnel and program expenses. SG&A expenses also rose to $13.9 million in Q3 2024, up from $13.4 million in the prior year period. These increases reflect NeuroPace's investment in strategic growth initiatives, which could be expected to continue in Q4 2024.
3. **Financial Health**: NeuroPace's cash burn was reduced to $1.8 million for Q3 2024, and the company increased its cash balance from $55.5 million at the end of Q2 to $56.8 million at the end of Q3, indicating strong financial health. This financial stability likely supported continued investment in growth initiatives and maintained operational efficiency.

In conclusion, NeuroPace likely experienced continued revenue growth and strategic expense management in Q4 2024, driven by strong market demand for its RNS System and effective cost control measures.